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cuantitative measurement of myocardial
perfusion has been a goal of cardiovascular
investigators for a number of years. Positron
emission tomography (PET) has allowed as-
sessment of myocardial blood flow in absolute value
(milliliters per gram per minute) (1) and is accurate at
dentifying both flow-limiting epicardial coronary artery
isease (CAD) as well as microvascular abnormalities.
ualitative cardiac magnetic resonance (CMR) stress
erfusion has also made clinical inroads of late, dem-
nstrating higher sensitivity and negative predictive
alue than single-photon emission computed tomogra-
hy (SPECT) in a head-to-head comparison of symp-
omatic patients against x-ray coronary angiography
mployed as the reference standard (2). Although the
easibility is established the more important question is
f we could do better with absolute quantitation of
yocardial blood flow? A recent comparative study of
ualitative versus quantitative analysis of myocardial
lood flow reserve with CMR did not demonstrate
ny incremental value of quantitative assessment for the
verall per patient accuracy, and this approach may be
easonable if the goal is to identify a patient with isch-
mia significant for justification of mechanical inter-
ention (3). However, the quantitative approach was
ore accurate for the assessment of pathophysiology in
ore detail such as the delineation of the amount of
yocardium at jeopardy.
Quantitative measures of myocardial blood flow
ave been validated over the years against microspheres
n animal models (4), usually on a per segment or per
ector level. In this issue of iJACC, Hsu et al. (5) take
his validation one step further, demonstrating accurate
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oth canines and humans with validation against mi-
rospheres in the former. A pixel comprising 32 l of
myocardium represented a remarkably small amount of
tissue. They demonstrated an outstanding agreement
between pixel-wise CMR myocardial blood flow esti-
mates and microspheres as well as excellent sector-wise
agreement. A substantial agreement was observed in
the clinically relevant range of myocardial blood flow at
rest and vasodilator stress and only began to fall off at
extremely high flows usually not clinically attained.
This study demonstrated remarkable spatial resolution
of CMR blood flow measures and allowed straightfor-
ward resolution of transmural differences in blood flow;
the resolution of CMR-verified blood flow gradient
was superior to the spatial resolution of the micro-
sphere measures. In fact, the clinical examples shown
in the paper clearly demonstrated the ability to resolve
the endocardial-to-epicardial blood flow differences
during vasodilator stress, which were not surprisingly
more profound in the setting of myocardial ischemia.
What are the limitations of this pixel-wise quantita-
tive approach? The analysis is at present laborious and
time-consuming, as each image has to be manually
segmented. The noise ratio may be higher with pixel
level measurements than those measuring and averag-
ing a larger volume of tissue. This presents a problem
with perfusion acquisitions, especially during vasodilator
stress, as both cardiac and respiratory motion is often
present. Nonrigid image registration is one potential fix
for this problem. Further validation in a multitude of
clinical settings will be necessary before this quantita-
tive approach could become widely applicable.
In what clinical settings will an ability to measure
pixel-wise myocardial blood flow become a difference-
maker? In addition to better identifying the extent of
myocardial ischemia, one could foresee using this ap-
proach to define microvascular dysfunction in condi-
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238tions such as the syndrome X. Whether subendocardial
perfusion is truly reduced in the patients with chest
pain and normal epicardial coronary arteries is still a
controversial question. Pixel-wise quantitative blood
flow measures could be just the ticket to resolve this
controversy. Diabetes is yet another clinical scenario
where the quantitation may allow better definition of
diffuse small vessel disease, regardless of the extent of
discrete epicardial stenoses. In the study by Patel et al.
(3), although underpowered to be definitive, diabetic
patients without epicardial CAD had equivalent blood
flow reserve to patients without diabetes with epicardial
CAD.
Research applications of such precise myocardial
flow data are quite obvious and it is very easy to be
overly enthusiastic about using pixel level CMR perfu-
sion in many clinical conditions. However, the clinical
utility of accurate myocardial blood flow quantitation
still remains untested despite many years of availability
in the PET arena. Right since the time of the early
studies in PET, there has been the lingering question
whether a precise (ml/min/mg of tissue) measurement
of myocardial blood flow adds clinical utility compared
to more global measurements in the territory of inter-
est. This question became even more contentious when
other measurements that were reasonably easy to ac-
quire and analyze (e.g., coronary flow reserve which
only need a ratio of before and after data), were shown
to be clinically relevant and helpful for therapeutic de-
cision-making. Thus, a pixel level CMR perfusion
technique, even though it is able to distinguish perfu-perfusion analysis. J Am Coll Cardiol
2010;56:561–9.
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Coll Cardiol Img 20endocardium, mid-myocardium, or epicardium) needs
to cross an even higher threshold of clinical rele-
vance—showing it is better than what is currently
available. At present, very few clinical conditions need
or indeed benefit from such pixel level precision.
Whether considered a curse or a boon, all emerging
technologies are competing in a new era of scientific
and economic scrutiny; they will face the challenge of a
need to cross a higher standard for usefulness and
show robustness in face of ever changing evaluation
criteria (e.g., outcomes over feasibility). Until it is able
show clinical utility, its current clinical role, pending
more comparative outcome data, may be more suited
to arbitrating deficiencies within current imaging tech-
niques (e.g., identifying false positives or artifacts, etc.).
Even though these newer and novel CMR techniques
are a big advance and will prove themselves as an accu-
rate tool, proving that ultra high resolution, pixel
level perfusion measurements are clinically necessary
will take a lot more study, despite their undoubted at-
tractiveness. We continue to be amazed by what CMR
technologies can achieve and thus chose to highlight
this paper. However, as evident in this and other previ-
ous Editor’s Pages (6–12), we are also optimistically
cautious about their clinical utility. To paraphrase Jef-
ferson, it is better to wait till the “froth settles down on
the cup of knowledge” before making optimistic judg-
ments. Cardiovascular imagers will be easily given the
gift of visualizing the myocardial flow with greater fi-
delity but will they be wiser for it should this come tosion abnormality in finite myocardial layers (e.g., sub- a pass remains a question with poor spatial resolution.R E F E R E N C E S
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